 |
 |
All I have been able to find is this Hans. Guilford entered into a corporate collaboration with Daiichi Radioisotope Laboratories (DRL) in December, 1995 for the commercialization of DOPASCAN® Injection in Japan, Korea, and Taiwan. DRL plans to initiate a Phase III clinical trial of DOPASCAN® Injection in the second half of 2000. This is the second half of 2000, so maybe they are having more trials, but I can't seem to find it. just me, Marjorie At 02:49 AM 09/08/2000 +0200, you wrote: >Hi all, > >The DOPASCAN, DATSCAN and ALTROPANE are three DIFFERENT agents >to diagnose PD. All three are in a different stage of development. >- DATSCAN is approved in Europe for the market. >- DOPASCAN is in a -to me- unclear phase after completing a trial in 1996. >( see >http://www.parkinson-study-group.org/Completed%20Clinical%20Trials.html ) >- ALTROPANE has just completed clinical trial Phase III. >( see article or http://biz.yahoo.com/bw/000727/ma_boston_.html ). > >Hans. > > >Thursday July 27, 9:29 am Eastern Time > >Company Press Release > >Boston Life Sciences' Altropane Successful in Phase III Study > >Parkinson's Disease Diagnostic Demonstrates Statistically Significant >Positive Results > >BOSTON--(BW HealthWire)--July 27, 2000--Boston Life Sciences, Inc. >(NASDAQ: BLSI - news) announced that the results of its Phase III clinical >trial of >Altropane as a diagnostic for Parkinson's Disease (``PD'') had successfully >confirmed Altropane's ability to differentiate Parkinson's movement >disorders (including Parkinson's Disease) from other movement disorders. The >primary efficacy endpoints, ``Specificity'' and ``Sensitivity'' were both >statistically significant. The Company's Phase II clinical trial previously >demonstrated Altropane's utility in differentiating normal patients from >those with PD. > >``We are delighted with these results which, we believe, document >Altropane's ability to reliably differentiate Parkinsonian from >non-Parkinsonian movement disorders,'' stated Dr. Marc Lanser, Chief >Scientific Officer of BLSI. ``We believe that the results obtained in this >study for Specificity and Sensitivity rank among the best reported for >approved diagnostic nuclear medicine agents in general, and are further >complemented by the excellent results achieved in our Phase II trial. It is >widely acknowledged that the accuracy of the initial clinical diagnosis of >PD by physicians needs to be improved. There is no other diagnostic for PD >in the U.S., either approved or in active clinical trials. We believe, >therefore, that Altropane could be a unique new and effective tool in >increasing the reliability of initial diagnosis, and thus aid in the >determination of appropriate therapy,'' added Dr. Lanser. > >The multi-center Phase III study was designed to assess the Sensitivity and >Specificity of Altropane-SPECT scanning in a sample population >representative of those individuals that consult with neurologists or >internists for undiagnosed movement disorders. The study enrolled 95 >subjects having the clinical diagnosis of Parkinsonian Syndrome (``PS'') and >70 patients having non-Parkinsonian Syndrome movement disorders with >clinical features similar to PS but whose symptoms are caused by something >other than a destruction of dopamine producing cells. These clinical >diagnoses were made by expert neurologists specializing in movement >disorders. Altropane SPECT scans were performed on each subject and were >reviewed by an independent three-member panel of nuclear medicine physicians >specializing in neuroimaging, who had no knowledge of the clinical >diagnosis. The Altropane scans were read and categorized as being consistent >with either PS or non-PS, and were then compared to the expert clinical >diagnosis. Specificity was 86%, Sensitivity was 75%, and overall accuracy >was 80%. ``Since clinical diagnosis has been shown to be wrong 25-30% of the >time, we believe that the excellent specificity shown by Altropane in this >study is particularly important,'' noted Dr. Lanser. Only six scans (out of >160) could not be read due to technical or other difficulties. There were no >Altropane-related adverse events reported in the study. The Company looks >forward to presenting the Phase III and other related data to the FDA. >However, there can be no assurance that these clinical results, or the >related safety and manufacturing data, will be sufficient for the filing of >an NDA or for approval of the product. > >BLSI is developing novel diagnostics and therapeutics for Parkinson's >Disease (PD) and Attention Deficit Hyperactivity Disorder (ADHD) as well as >treatments for cancer, autoimmune disease, and central nervous system >disorders. BLSI's products in development include: Altropane, a radioimaging >agent for the diagnosis of PD and ADHD; Troponin I, a naturally-occurring >anti-angiogenesis factor for the treatment of solid tumors; AF-1 and >Inosine, nerve growth factors for the treatment of acute and chronic CNS >disorders; novel therapies for the treatment of PD and ADHD; and >transcription factors that may control the expression of molecules >associated with autoimmune disease and allergies. > >Statements made in this press release other than statements of historical >fact represent forward-looking statements. Such statements include, without >limitation, statements regarding expectations or beliefs as to future >results or events, such as the expected timing and results of clinical >trials, discussions with regulatory agencies, schedules of IND, NDA and all >other regulatory submissions, the timing of product introductions, the >possible approval of products, and the market size and possible advantages >of the Company's products. All such forward-looking statements involve >substantial risks and uncertainties, and actual results may vary materially >from these statements. Factors that may affect future results include: the >availability and adequacy of financial resources, the ability to obtain >intellectual property protection, delays in the regulatory or development >processes, results of scientific data from clinical trials, the outcome of >discussions with potential partners, regulatory decisions, market acceptance >of the Company's products, and other possible risks and uncertainties that >have been noted in reports filed by the Company with the Securities and >Exchange Commission, including the Company's Annual Report on Form 10-K. > >Contact: > > Boston Life Sciences, Inc. > Maria Zapf > 617.425.0200, ext.17 > www.bostonlifesciences.com > or > The Trout Group > Brandon Lewis > 212.477.9007, ext. 15 > www.troutgroup.com > or > Boston Life Sciences, Inc. > Marc Lanser, MD > 617.425.0200 > or > Schwartz Communications > Jim Weinrebe > 781.684.0770 > www.schwartz-pr.com > >Copyright © 2000 Yahoo! All Rights Reserved.